targeted therapies have revolutionized its treatment, moving therapeutic intervention from the try-and-see approach to a rational, individually based algorithm remains an elusive goal. The main reason for this is that RA is a highly heterogeneous clinical and pathobiological condition, characterized by a diverse disease evolution and response to therapy. Interestingly, although at group level the response to biologic therapies appear to be stereotypically similar, with a comparable ACR20 (60%), ACR50 (40%), ACR70 (20%) response rates to all agents (TNF inhibitors, rituximab, tocilizumab, abatacept) , individual patients who fail one mechanism of action by one drug are not necessarily the same as those failing a different mechanism of action by another. Thus, the search for biomarkers capable of predicting response to biologic therapies has been a research focus for many years. However, no reliable makers have been so far identified in the peripheral blood where, for example, gene expression profiles, as pharmacological signatures, were significantly modulated post-TNF blockade in all patients irrespective of clinical response. On the other hand, we have recently reviewed published evidence reporting that specific pathways within synovial tissues are associated with diverse clinical evolution and therapeutic response/resistance. The next challenge is to determine in randomized clinical trials (RCTs) the relationship and predictive value of different synovial pathotypes (and associated molecular signatures) with therapeutic response/resistance. This may lead to the development of synovial tissue analysis as a potential clinical tool for patient stratification and construct predictive algorithms incorporating pathobiology into existing clinical, laboratory and imaging modalities, if not for all, at least for the most difficult patients. The establishment of US-guided synovial biopsy as a rapid, safe and well-tolerated procedure in the hands of rheumatologists that enables synovial tissue collection from most joints in most patients, combined with the development high-throughput miniaturized technologies, should facilitate testing the clinical utility of synovial pathobiology in appropriately powered RCT. This lecture will review current literature on synovial biomarkers and the rationale for considering integrating synovial pathobiology into clinical therapeutic algorithms to predict therapeutic response to biologic therapies to personalize treatment in RA. Disclosure statement: C.P. has acted as a consultant and/or received research funds through his institutions from AbbVie, Amgen, Genentech/Roche, Janssen/J&J, MedImmune/AZ, UCB and Pfizer. OA is regarded as a complex disease whose cause is not completely understood. Increases in life expectancy and ageing populations will make OA the fourth leading cause of disability by the year 2020. The number of people with OA in the UK is increasing as the population ages and as risk factors for OA also continue to rise. But it is wrong to believe that OA is just part of getting older and that nothing can be done. High quality research and clinical guidelines have recommended effective treatments such as support for self-management, exercise and joint protection education. However, even best evidence is not automatically taken up into practice. For primary care in particular the challenge of supporting patients with self-management in consultations for OA cannot be underestimated. The Droitwich lecture will give a case example of how best evidence can be implemented into practice through model OA consultations for the benefit of patients, health care professionals and services. The lecture will illustrate how partnerships between researchers, health care professionals and patients can also maximize the impact of best evidence for OA in the future. RA is a chronic inflammatory condition that affects 1% of the population and is characterized by synovial inflammation and destruction of cartilage and bone, leading to progressive disability and reduced life expectancy. Cytokines play an important role in these processes, a fact highlighted by the clinical effectiveness of anti-cytokine therapeutic interventions. However it is still unclear what regulates cytokine production and what prolongs the inflammatory and tissue-destructive mediators in RA. Toll like receptors (TLRs), the inflammasome as well as complement have all been individually linked to RA. Several ligands linked with RA can activate all three of these receptors, but whether and how these three systems interact with each other in the context of RA has not been previously studied. In the current study we investigated whether interplay between these receptors is the key to the chronic inflammatory response observed in RA. We have demonstrated that these three classes of pattern recognition receptors co-operate leading to a chronic inflammatory response in synovial fibroblasts. By deciphering the molecular mechanisms involved, we will be able to identify novel therapeutic targets for RA in the future. To complete training, the minimum requirements to obtain CCT are plainly outlined in the curriculum, at ARCPs and PYA. However to compete successfully for jobs post-CCT it is desirable to have an enhanced CV which might reflect a wider understanding and experience of a number of issues relevant to the healthcare environment into which trainees are then launched. Therefore gaining knowledge of the healthcare environment-the political and financial drivers of changes in manpower, training, governance, commissioning, validation etc. are key issues for all consultants once the new job starts. Being cognisant of these issues and being able to deal with them at interview and from the get-go in a new consultant job would be highly advantageous for all trainees planning to work in The NHS or in
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